{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:08:35Z","timestamp":1791918515670,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.pharmthera.2020.107504","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T03:18:20Z","timestamp":1582255100000},"page":"107504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus"],"prefix":"10.1016","volume":"209","author":[{"given":"Marwa M.","family":"Nagib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107504_bb0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2007.10.008","article-title":"Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism","volume":"78","author":"Akula","year":"2008","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.prostaglandins.2009.04.003","article-title":"Emerging roles of PGE2 receptors in models of neurological disease","volume":"91","author":"Andreasson","year":"2010","journal-title":"Prostaglandins and Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0006-8993(99)01797-7","article-title":"Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus","volume":"843","author":"Baik","year":"1999","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0079-6123(02)35033-7","article-title":"Is neuronal death required for seizure-induced epileptogenesis in the immature brain?","volume":"135","author":"Baram","year":"2002","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.expneurol.2012.01.028","article-title":"Neuronal circuits in epilepsy: Do they matter?","volume":"244","author":"Bertram","year":"2013","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0030","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jama.2019.0441","article-title":"Emergency medical services protocols for generalized convulsive status epilepticus","volume":"321","author":"Betjemann","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5698\/1535-7597-14.1.35","article-title":"StEPing \u201cEP2\u201d to prevent status epilepticus-induced mortality and inflammation","volume":"14","author":"Bhuyan","year":"2014","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/ecp.13.12","article-title":"Epilepsy in glioblastoma patients: Basic mechanisms and current problems in treatment","volume":"6","author":"Bruna","year":"2013","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.joen.2015.12.011","article-title":"Prostaglandin E2 stimulates EP2, adenylate cyclase, phospholipase C, and intracellular calcium release to mediate cyclic adenosine monophosphate production in dental pulp cells","volume":"42","author":"Chang","year":"2016","journal-title":"Journal of Endodontics"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12035-014-8889-0","article-title":"PGE2 inhibits IL-10 production via EP2-mediated beta-Arrestin signaling in Neuroinflammatory condition","volume":"52","author":"Chu","year":"2015","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12028-017-0460-1","article-title":"Emergency neurological life support: Status epilepticus","volume":"27","author":"Claassen","year":"2017","journal-title":"Neurocritical Care"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0920-1211(99)00119-9","article-title":"Temporal profile of neuronal injury following pilocarpine or kainic acid-induced status epilepticus","volume":"39","author":"Covolan","year":"2000","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0065","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nprot.2006.170","article-title":"Assessing nest building in mice","volume":"1","author":"Deacon","year":"2006","journal-title":"Nature Protocols"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2009.02.005","article-title":"Comparisons of the mortality and clinical presentations of status epilepticus in private practice community and university hospital settings in Richmond, Virginia","volume":"18","author":"DeLorenzo","year":"2009","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tips.2016.03.001","article-title":"Anti-inflammatory small molecules to treat seizures and epilepsy: From bench to bedside","volume":"37","author":"Dey","year":"2016","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13543784.2019.1557147","article-title":"An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders","volume":"28","author":"Dhir","year":"2019","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-94-017-8914-1_9","article-title":"When and how do seizures kill neurons, and is cell death relevant to epileptogenesis?","volume":"813","author":"Dingledine","year":"2014","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/14737175.2016.1134322","article-title":"Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus","volume":"16","author":"Du","year":"2016","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5698\/1535-7511-12.3.115","article-title":"Mechanisms of seizure-induced inflammation of the brain: Many possible roles for neuronal COX-2","volume":"12","author":"Dudek","year":"2012","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1528-1157.44.s10.4.x","article-title":"Epidemiology of posttraumatic epilepsy: A critical review","volume":"44","author":"Frey","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/mol.115.098202","article-title":"EP2 receptor signaling regulates microglia death","volume":"88","author":"Fu","year":"2015","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmech.2014.05.076","article-title":"Development of second generation EP2 antagonists with high selectivity","volume":"82","author":"Ganesh","year":"2014","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0115","unstructured":"Ganesh, T., Jiang, J., & Dingledine, R. J. (2018). Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto. US Patent, US10052332B2."},{"key":"10.1016\/j.pharmthera.2020.107504_bb0120","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/ml400112h","article-title":"Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists","volume":"4","author":"Ganesh","year":"2013","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0125","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1021\/jm5000672","article-title":"Lead optimization studies of cinnamic amide EP2 antagonists","volume":"57","author":"Ganesh","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-011209-153129","article-title":"Emotion recollected in tranquility: Lessons learned from the COX-2 saga","volume":"61","author":"Grosser","year":"2010","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0135","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.96.18.10501","article-title":"Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2)","volume":"96","author":"Hizaki","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.nbd.2015.03.026","article-title":"Contribution of protease-activated receptor 1 in status epilepticus-induced epileptogenesis","volume":"78","author":"Isaev","year":"2015","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tips.2013.05.003","article-title":"Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection","volume":"34","author":"Jiang","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0150","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.112.200444","article-title":"Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation","volume":"344","author":"Jiang","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0155","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1073\/pnas.1120195109","article-title":"Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2","volume":"109","author":"Jiang","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0160","unstructured":"Jiang, J., Ganesh, T., Du, Y., Thepchatri, P., Quan, Y., & Dingledine, R. J. (2016). Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto. US Patent, US9518044B2."},{"key":"10.1016\/j.pharmthera.2020.107504_bb0165","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.0909310107","article-title":"Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor","volume":"107","author":"Jiang","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trecan.2016.12.002","article-title":"Prostaglandin E2 signaling: Alternative target for glioblastoma?","volume":"3","author":"Jiang","year":"2017","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0175","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1073\/pnas.1218498110","article-title":"Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation","volume":"110","author":"Jiang","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0180","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acschemneuro.7b00486","article-title":"Discovery of 2-Piperidinyl phenyl Benzamides and Trisubstituted pyrimidines as positive allosteric modulators of the prostaglandin receptor EP2","volume":"9","author":"Jiang","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0185","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.12.032","article-title":"Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus","volume":"76","author":"Jiang","year":"2015","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuropharm.2019.02.011","article-title":"Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury","volume":"149","author":"Jiang","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0195","doi-asserted-by":"crossref","first-page":"16016","DOI":"10.1523\/JNEUROSCI.2203-13.2013","article-title":"Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia","volume":"33","author":"Johansson","year":"2013","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1172\/JCI77487","article-title":"Prostaglandin signaling suppresses beneficial microglial function in Alzheimer\u2019s disease models","volume":"125","author":"Johansson","year":"2015","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-6606-5-14","article-title":"The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB","volume":"5","author":"Kandel","year":"2012","journal-title":"Molecular Brain"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0210","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/NDT.S50371","article-title":"Animal models of epilepsy: Use and limitations","volume":"10","author":"Kandratavicius","year":"2014","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0215","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1038\/s41598-017-09528-z","article-title":"Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype","volume":"7","author":"Kang","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0220","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0002-9440(10)65199-1","article-title":"Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2","volume":"155","author":"Kelley","year":"1999","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/5583","article-title":"Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor","volume":"5","author":"Kennedy","year":"1999","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0773.2001.880509.x","article-title":"Nimesulide aggravates kainic acid-induced seizures in the rat","volume":"88","author":"Kunz","year":"2001","journal-title":"Pharmacology & Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0235","doi-asserted-by":"crossref","DOI":"10.1177\/1759091415578713","article-title":"Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery","volume":"7","author":"Leclerc","year":"2015","journal-title":"ASN Neuro"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0240","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.neubiorev.2013.10.011","article-title":"The kainic acid model of temporal lobe epilepsy","volume":"37","author":"Levesque","year":"2013","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0245","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1528-1167.2012.03584.x","article-title":"Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene","volume":"53","author":"Levin","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0250","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1523\/JNEUROSCI.3591-05.2005","article-title":"Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer\u2019s disease","volume":"25","author":"Liang","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0255","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.21437","article-title":"The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis","volume":"64","author":"Liang","year":"2008","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0260","first-page":"107734","article-title":"Targeting BDNF\/TrkB pathways for preventing or suppressing epilepsy","author":"Lin","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0265","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1073\/pnas.1818544116","article-title":"PGE2 signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia","volume":"116","author":"Liu","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Suppl. 12","key":"10.1016\/j.pharmthera.2020.107504_bb0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1528-1167.2009.02367.x","article-title":"Molecular mechanisms of drug resistance in status epilepticus","volume":"50","author":"Loscher","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0275","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"Loscher","year":"2013","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0280","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1528-1167.2007.00988.x","article-title":"Seizure-promoting effect of blood-brain barrier disruption","volume":"48","author":"Marchi","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0285","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.59.2.205","article-title":"Refractory status epilepticus: Frequency, risk factors, and impact on outcome","volume":"59","author":"Mayer","year":"2002","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.01.009","article-title":"The role of glucuronidation in drug resistance","volume":"159","author":"Mazerska","year":"2016","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1523\/JNEUROSCI.4485-03.2004","article-title":"Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia","volume":"24","author":"McCullough","year":"2004","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0300","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0305","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/nyas.13147","article-title":"Benzodiazepine-refractory status epilepticus: Pathophysiology and principles of treatment","volume":"1378","author":"Niquet","year":"2016","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eplepsyres.2007.12.008","article-title":"Cyclooxygenase-2\/PGE2 pathway facilitates pentylenetetrazol-induced seizures","volume":"79","author":"Oliveira","year":"2008","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0315","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5698\/1535-7597.17.5.293","article-title":"Novel Targets for Developing Antiseizure and, Potentially, Antiepileptogenic Drugs","volume":"17","author":"Patel","year":"2017","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0320","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/nyas.13137","article-title":"Models to identify treatments for the acute and persistent effects of seizure-inducing chemical threat agents","volume":"1378","author":"Pessah","year":"2016","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0325","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1474-4422(15)00248-3","article-title":"Development of epilepsy after ischaemic stroke","volume":"15","author":"Pitkanen","year":"2016","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0330","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bph.14622","article-title":"Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth","volume":"176","author":"Qiu","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0335","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1074\/jbc.M113.455816","article-title":"EP2 receptor signaling pathways regulate classical activation of microglia","volume":"288","author":"Quan","year":"2013","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0340","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nbd.2003.08.001","article-title":"Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development","volume":"14","author":"Rizzi","year":"2003","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.neuropharm.2015.01.017","article-title":"Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus","volume":"93","author":"Rojas","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0350","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neuropharm.2016.07.028","article-title":"Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats","volume":"110","author":"Rojas","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0355","doi-asserted-by":"crossref","first-page":"104399","DOI":"10.1016\/j.nbd.2019.02.010","article-title":"A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition","volume":"133","author":"Rojas","year":"2020","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/epi.12461","article-title":"Cyclooxygenase-2 in epilepsy","volume":"55","author":"Rojas","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0365","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.expneurol.2009.01.016","article-title":"Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor","volume":"217","author":"Savonenko","year":"2009","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0370","doi-asserted-by":"crossref","first-page":"14850","DOI":"10.1523\/JNEUROSCI.3922-11.2011","article-title":"Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus","volume":"31","author":"Serrano","year":"2011","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0375","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pharmthera.2011.04.008","article-title":"Promise of resveratrol for easing status epilepticus and epilepsy","volume":"131","author":"Shetty","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0380","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.lfs.2005.08.026","article-title":"Prostaglandin E2 deteriorates N-methyl-D-aspartate receptor-mediated cytotoxicity possibly by activating EP2 receptors in cultured cortical neurons","volume":"78","author":"Takadera","year":"2006","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0385","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI6579","article-title":"Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor","volume":"103","author":"Tilley","year":"1999","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0390","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.eplepsyres.2012.04.014","article-title":"Characterization of status epilepticus induced by two organophosphates in rats","volume":"101","author":"Todorovic","year":"2012","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0395","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2016.02.014","article-title":"Repeated low-dose kainate administration in C57BL\/6J mice produces temporal lobe epilepsy pathology but infrequent spontaneous seizures","volume":"279","author":"Umpierre","year":"2016","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0405","first-page":"395566","article-title":"Opposing effects of prostaglandin receptor EP2 signaling in mouse immune cells and neurons after status epilepticus","author":"Varvel","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0410","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-pharmtox-010814-124607","article-title":"Candidate drug targets for prevention or modification of epilepsy","volume":"55","author":"Varvel","year":"2015","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0415","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00401-015-1481-5","article-title":"Infections, inflammation and epilepsy","volume":"131","author":"Vezzani","year":"2016","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0420","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/brain\/awl318","article-title":"Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy","volume":"130","author":"van Vliet","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0425","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1172\/JCI92001","article-title":"Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy","volume":"127","author":"Walker","year":"2017","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0430","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pharmthera.2019.05.010","article-title":"An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy","volume":"201","author":"Wang","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0435","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1471-4159.2008.05766.x","article-title":"Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor","volume":"108","author":"Yang","year":"2009","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2020.107504_bb0440","doi-asserted-by":"crossref","first-page":"101682","DOI":"10.1016\/j.pneurobio.2019.101682","article-title":"G protein-coupled receptors in acquired epilepsy: Druggability and translatability","volume":"183","author":"Yu","year":"2019","journal-title":"Progress in Neurobiology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:03:04Z","timestamp":1759010584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":88,"alternative-id":["S0163725820300322"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107504","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107504"}}